MX419987B - RADIOLUMINESCENT LUTETIUM-177 SESQUIOXIDE NANOPARTICLES FUNCTIONALIZED WITH PEPTIDES FOR OPTICAL IMAGING. - Google Patents

RADIOLUMINESCENT LUTETIUM-177 SESQUIOXIDE NANOPARTICLES FUNCTIONALIZED WITH PEPTIDES FOR OPTICAL IMAGING.

Info

Publication number
MX419987B
MX419987B MX2021005088A MX2021005088A MX419987B MX 419987 B MX419987 B MX 419987B MX 2021005088 A MX2021005088 A MX 2021005088A MX 2021005088 A MX2021005088 A MX 2021005088A MX 419987 B MX419987 B MX 419987B
Authority
MX
Mexico
Prior art keywords
lutetium
sesquioxide
nanoparticles
sizes
vivo
Prior art date
Application number
MX2021005088A
Other languages
Spanish (es)
Other versions
MX2021005088A (en
Inventor
Cortez Alejandra Ancira
García Blanca Eli Ocampo
Cuevas Clara Leticia Santos
BENÍTEZ Diana Sarahí TRUJILLO
Avila Enrique Morales
Flores Guillermina Ferro
Gutiérrez Myrna Alejandra Luna
Mancilla Nallely Patricia Jiménez
Original Assignee
Instituto Nac De Investigaciones Nucleares
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto Nac De Investigaciones Nucleares filed Critical Instituto Nac De Investigaciones Nucleares
Priority to MX2021005088A priority Critical patent/MX419987B/en
Priority to PCT/MX2021/050056 priority patent/WO2022231411A1/en
Publication of MX2021005088A publication Critical patent/MX2021005088A/en
Publication of MX419987B publication Critical patent/MX419987B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
    • C01F17/00—Compounds of rare earth metals
    • C01F17/20—Compounds containing only rare earth metals as the metal element
    • C01F17/206—Compounds containing only rare earth metals as the metal element oxide or hydroxide being the only anion
    • C01F17/224—Oxides or hydroxides of lanthanides
    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
    • G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
    • G21G1/04—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes outside nuclear reactors or particle accelerators
    • G21G1/06—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes outside nuclear reactors or particle accelerators by neutron irradiation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Composite Materials (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Geology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to a novel system based on lutetium sesquioxide nanoparticles with high purity and crystallinity according to their crystallographic planes obtained by XDR and indexed to crystallographic charts JCPSD No.12-0728 (Lu2O3) of quasi spherical morphology with sizes of up 20nm to 45 nm. Said nanoparticles are radio luminescent by neutron irradiation (177Lu2O3) activation, presenting luminescence emission spectra in the near-infrared region with an emission maximum at ~615 nm, obtaining in vivo optical images of its biodistribution. After functionalization with a prostate-specific membrane antigen (PSMA) inhibitory peptide, lutetium sesquioxide nanoparticles increase their sizes up 30nm to 50 nm, presenting vibration bands corresponding to their functional groups by FT-IR spectroscopy replicated in the absorption bands of the observed UV-Vis spectra. Additionally, the zeta potential values ??in all systems maintain an absolute value higher than 25 mV, which impl ies high stability of the colloidal system. Further, the present invention aims to provide a novel specific nano system (molecular target radiopharmaceutical) with potential application in nanomedicine as a dual imaging agent (optical and nuclear) in vivo and precise molecular target radiotherapy.
MX2021005088A 2021-04-30 2021-04-30 RADIOLUMINESCENT LUTETIUM-177 SESQUIOXIDE NANOPARTICLES FUNCTIONALIZED WITH PEPTIDES FOR OPTICAL IMAGING. MX419987B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2021005088A MX419987B (en) 2021-04-30 2021-04-30 RADIOLUMINESCENT LUTETIUM-177 SESQUIOXIDE NANOPARTICLES FUNCTIONALIZED WITH PEPTIDES FOR OPTICAL IMAGING.
PCT/MX2021/050056 WO2022231411A1 (en) 2021-04-30 2021-10-15 Peptide-functionalised radioluminescent lutetium sesquioxide-177 nanoparticles for optical imaging

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2021005088A MX419987B (en) 2021-04-30 2021-04-30 RADIOLUMINESCENT LUTETIUM-177 SESQUIOXIDE NANOPARTICLES FUNCTIONALIZED WITH PEPTIDES FOR OPTICAL IMAGING.

Publications (2)

Publication Number Publication Date
MX2021005088A MX2021005088A (en) 2022-11-01
MX419987B true MX419987B (en) 2025-01-14

Family

ID=83847160

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005088A MX419987B (en) 2021-04-30 2021-04-30 RADIOLUMINESCENT LUTETIUM-177 SESQUIOXIDE NANOPARTICLES FUNCTIONALIZED WITH PEPTIDES FOR OPTICAL IMAGING.

Country Status (2)

Country Link
MX (1) MX419987B (en)
WO (1) WO2022231411A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11130675B2 (en) * 2011-09-02 2021-09-28 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Flame spray synthesis of nanoparticles of monoclinic Lu203 and dopant
US20150240156A1 (en) * 2012-09-11 2015-08-27 Mingjie Zhou Lutecium oxide luminescent material and preparation method thereof
MX380340B (en) * 2018-03-14 2025-03-11 Instituto Nac De Investigaciones Nucleares 177LU-DOTA-HYNIC-IPSMA AS A THERAPEUTIC RADIOPHARMACO DIRECTED AT THE PROSTATIC MEMBRANE-SPECIFIC ANTIGEN.

Also Published As

Publication number Publication date
MX2021005088A (en) 2022-11-01
WO2022231411A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
EP4338799A3 (en) Tumor infiltrating lymphocytes and methods of therapy
Zheng et al. Targeted cancer cell inhibition using multifunctional dendrimer-entrapped gold nanoparticles
BR112023017947A2 (en) METHOD OF PRODUCING A CO-PRECIPTATE
MX2020000413A (en) A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers.
CR20220530A (en) HUMAN INTERLEUKIN-2 CONJUGATES BIASED FOR THE INTERLEUKIN-2 RECEPTOR BETA GAMMAc DIMER AND CONJUGATED TO A NONPEPTIDIC, WATER-SOLUBLE POLYMER
US20170073392A1 (en) Cd44 binding peptides
MX358321B (en) Anti-ceacam5 antibodies and uses thereof.
He et al. Water-ultrastable perovskite CsPbBr3 nanocrystals for fluorescence-enhanced cellular imaging: C.-L. He et al.
TW200726774A (en) Composition and method for producing stable amyloid beta oligomers
ZA201503004B (en) Novel mucosal adjuvants and delivery systems
CL2021000496A1 (en) Crosslinking particle gel for co2 compliance control and co2 filtration blocking.
MX419987B (en) RADIOLUMINESCENT LUTETIUM-177 SESQUIOXIDE NANOPARTICLES FUNCTIONALIZED WITH PEPTIDES FOR OPTICAL IMAGING.
EP4549478A4 (en) Core-shell fluorocarbon-based resin particles with improved flowability and flocculation, as well as manufacturing process.
ATE460715T1 (en) THREE-DIMENSIONAL TIME-OF-FLIGHT PET WITH COARSE ANGLE AND DISC REBINNING
BR112015029021A2 (en) compact polymer gel and fibers made from it
BR112021006643A8 (en) COMPOSITIONS AND METHODS TO INCREASE SYSTEMIC DELIVERY CAPACITY, TOLERANCE AND EFFECTIVENESS OF MACROCYCLIC CATIONIC PEPTIDES
Murugan et al. Correction: Corrigendum: Combinatorial nanocarrier based drug delivery approach for amalgamation of anti-tumor agents in breast cancer cells: an improved nanomedicine strategy
RU2013131625A (en) METHOD FOR PRODUCING PARTICLES OF AN ENAPSULATED FAT-SOLUBLE POLYMERIC UNABY ENVELOPE Possessing SUPRAMOLECULAR PROPERTIES
PE20241806A1 (en) 177Lu PRODUCTION FROM Yb TARGETS
BRPI0707247B8 (en) tumor vaccine comprising allogeneic or xenogeneic tumor cells
WO2024249501A3 (en) B7h3 miniprotein conjugates
Cudjoe et al. Correction to “Strong, Rebondable, Dynamic Cross-Linked Cellulose Nanocrystal Polymer Nanocomposite Adhesives”
WO2013144301A3 (en) Easily purifiable synthon composition
SUN et al. Clinical application of CT perfusion imaging in assessment of gastric cancer
Chantal et al. Synthesis of Hydrophilic CuInS2/ZnS Quantum Dots with Different Polymeric Shells and Study of Their Cytotoxicity and Hemocompatibility